Akari Therapeutics (NASDAQ:AKTX) Shares Pass Above 50 Day Moving Average – Here’s What Happened

Akari Therapeutics PLC (NASDAQ:AKTX)’s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $7.39 and traded as high as $16.10. Akari Therapeutics shares last traded at $15.07, with a volume of 60,086 shares.

Analyst Ratings Changes

A number of equities analysts recently commented on AKTX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akari Therapeutics in a research note on Monday, April 20th. Maxim Group lowered Akari Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th. Finally, HC Wainwright lifted their price objective on Akari Therapeutics to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, April 1st. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Akari Therapeutics has a consensus rating of “Hold” and an average target price of $89.00.

Akari Therapeutics Stock Down 4.9%

The stock has a 50 day moving average of $7.39 and a 200 day moving average of $9.97.

Akari Therapeutics (NASDAQ:AKTX) last issued its quarterly earnings results on Wednesday, May 20th. The biopharmaceutical company reported ($688.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($686.67).

Hedge Funds Weigh In On Akari Therapeutics

A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC purchased a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned 5.95% of Akari Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.